NCT00738985

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease.

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To measure the percentage of patients who achieve all the treatment lipid goals being treated with ezetimibe/simvastatin 10/20 with or without MK0524A (1-2 g/day).

Detailed description

Patients will receive placebo for 4 weeks, then Vytorin 10/20 mg for 6 weeks, if efficacy of treatment is achieved, they will continue with Vytorin 10/20 mg + placebo for 12 more weeks, if not achieved, will receive Vytorin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with Vytorin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive Vytorin 10/20 mg + MK0524A 2 gr for 6 weeks.

Conditions

• Cardiovascular Diseases
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	ezetimibe/simvastatin 10/20 mg + placebo	Patients will receive placebo (sugar tablets) for up to 22 weeks.
DRUG	ezetimibe/simvastatin 10/20 mg + MK0524A	ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets

Timeline

• Start date: 2009-11-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2008-08-21
• Last updated: 2015-03-24